drugset / Trial / NCT03154918

GLIDE Regimen Followed by ASCT for Aggressive NK/T Cell Lymphoma

NCT03154918

Phase 2 Unknown 60 enrolled Sichuan University
NaSingle-groupOpen-labelTreatment

Summary

This study is to explore the efficacy and safety of GLIDE regiment in patients with aggressive NK/T cell lymphoma.

Timeline

Start
2017-06-01
Primary completion
2020-12-31
Completion
2021-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 20 mg
Subject Etoposide Small molecule 100 mg/m2
Subject Gemcitabine Small molecule 800 mg/m2
Subject Ifosfamide Small molecule 1000 mg/m2
Subject Pegaspargase Protein / enzyme biologic 2500 unknown